Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS: https://t.co/mwb6TCjjze

Mesoblast more than doubled after it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients.

$MESO #COVID-19 #stocks @Mesoblast https://t.co/LLtFoWCLQk